ImmunoPrecise Antibodies Ltd. Capital Reinvestment Ratio

Latest as of October 2020: 1.62x

ImmunoPrecise Antibodies Ltd. capital reinvestment ratio. ImmunoPrecise Antibodies Ltd. (HYFT) has a Capital Reinvestment Ratio of 1.62x as of October 2020, meaning it reinvests 2% of its operating cash flow ($440.23K) in capital expenditures ($715.21K). Check ImmunoPrecise Antibodies Ltd. (HYFT) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

1.62x

Capex / Operating Cash Flow

Operating Cash Flow

$440.23K

USD

Capital Expenditures

$715.21K

USD

Data as of

Oct 2020

Most recent filing

Capital Reinvestment Ratio of ImmunoPrecise Antibodies Ltd. (2016–2016)

Capital reinvestment ratio of ImmunoPrecise Antibodies Ltd. from 2016 to 2016. This chart tracks ImmunoPrecise Antibodies Ltd.'s Capital Reinvestment Ratio across 1 annual periods. Also explore HYFT net asset momentum to track the company's year-over-year net asset growth rate.

ImmunoPrecise Antibodies Ltd. Capital Reinvestment Ratio by Year (2016–2016)

ImmunoPrecise Antibodies Ltd. capital reinvestment ratio by year from 2016 to 2016. For the full cash flow conversion analysis, see cash efficiency ratio of ImmunoPrecise Antibodies Ltd..

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2016	0.06x	$284.09K	$17.48K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow